Riverview Community Mental Health Center
584 Northwest University Boulevard, Suite 300, Port St. Lucie
3.8(52 Google reviews)
United States
2 listed treatment centers serving Port St. Lucie and the surrounding area.
584 Northwest University Boulevard, Suite 300, Port St. Lucie
3.8(52 Google reviews)
1100 Saint Lucie West Boulevard, 203, Port St. Lucie
4.6(36 Google reviews)
For people in Port St. Lucie considering SPRAVATO®, understanding the full billing process matters as much as checking whether the medication is covered. The medication and the visit for supervised administration and monitoring may be billed separately. Ask for an estimate that includes both, along with any evaluation or follow-up charges.
Coverage varies by plan. Prior authorization is common, and your insurer may request documentation of earlier antidepressant trials. Ask your prescriber what records are needed, such as medication names, treatment dates, and how you responded. Having records available can help the team prepare the request, but does not guarantee approval.
Medicare coverage may fall under Part B or Part D depending on the plan and treatment setting. Florida Medicaid coverage also depends on the plan and setting. The two Port St. Lucie listings in this directory are marked as not accepting Medicare or Medicaid; confirm current participation directly before scheduling. Those listings do not establish what your insurance will cover elsewhere.
Manufacturer savings programs exist for eligible commercially insured patients, not people using government insurance. Ask about current eligibility rules and which charges a program addresses rather than assuming it pays for the whole visit.
Before starting, ask the center and your insurer:
SPRAVATO® treatment requires visits to a REMS-certified healthcare setting. You self-administer the nasal spray under a healthcare provider’s direct observation; it is never sent home with you. This directory lists two Port St. Lucie centers offering Spravato, but their REMS certification status is not recorded. Confirm certification and appointment availability directly before making plans.
For treatment-resistant depression, the typical labeled schedule starts with twice-weekly visits during weeks 1–4, followed by weekly visits during weeks 5–8. Maintenance may be weekly or every two weeks, individualized by your prescriber. Your own schedule depends on your treatment plan, so do not assume a fixed number of visits.
Monitoring lasts at least two hours after each dose. Allow additional time for check-in, preparation, and any longer observation your care team considers necessary. When arranging time off work, account for the appointment, transportation, and recovery afterward. You must not drive or operate machinery until the next day after a restful sleep.
Arrange for someone else to take you home after every visit. Ask the center about its pickup requirements before relying on a taxi or rideshare, and consider a backup ride if your usual driver becomes unavailable.
If no Port St. Lucie center is listed when you search, or local appointments are unavailable, this directory also lists centers in West Palm Beach, Miami, Hollywood, Orlando, Tampa, Jacksonville, St. Petersburg, and Clearwater. Confirm certification, insurance participation, and availability before committing to travel. Consider whether repeated trips and reliable return rides are manageable for you.
This directory lists two Port St. Lucie centers offering SPRAVATO®, but their REMS certification status is not recorded. Ask each center to confirm that treatment takes place in a currently REMS-certified setting. Also ask whether it is accepting new patients, how evaluations are scheduled, and whether it participates in your insurance network.
Spravato is FDA-approved for adults with treatment-resistant depression, alone or with an oral antidepressant. It is also approved for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, together with an oral antidepressant. It is not approved for children. A clinician must review your history and safety risks to determine whether it is appropriate.
Coverage depends on your plan, the treatment setting, and authorization requirements. Insurers commonly request records of earlier antidepressant trials. Ask about coverage for both the medication and monitoring visit. The two local directory listings are marked as not accepting Medicare or Medicaid; verify this directly. That information does not mean those programs cannot cover treatment at another participating setting.
You use the nasal spray yourself under a healthcare provider’s direct observation in a REMS-certified setting. The team monitors you for at least two hours after the dose, including watching your blood pressure and checking for sedation, dissociation, and breathing problems. Arrange a ride home: you cannot drive or operate machinery until the next day after a restful sleep.
Important risks include sedation, dissociation—feeling disconnected from yourself or your surroundings—respiratory depression, and blood pressure increases. Spravato carries boxed warnings for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors. It is a Schedule III controlled substance. Discuss your medical history, medications, and substance-use history so the clinician can assess your individual risks.
No. Spravato has not been shown to prevent suicide or reduce suicidal thoughts or behavior, and it does not replace hospitalization when clinically needed. Do not wait for a treatment appointment if you need urgent help. Call or text 988 for crisis support, or call 911 in an immediate emergency.
Approved uses, nearby treatment centers, and medically sourced patient guides.